Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN

Market Cap$358.55M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Myriad Genetics, Inc.Myriad Genetics, Inc.-3--16%0.50.2
$11.00

Target Price by Analysts

167.6% upsideMyriad Genetics Target Price DetailsTarget Price
$-8.81

Current Fair Value

314.4% downside

Overvalued by 314.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$358.55 Million
Enterprise Value$405.95 Million
Dividend Yield$0 (0%)
Earnings per Share$-3.18
Beta2.02
Outstanding Shares90,900,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-3.05
PEG4.77
Price to Sales0.46
Price to Book Ratio0.51
Enterprise Value to Revenue0.49
Enterprise Value to EBIT-3.66
Enterprise Value to Net Income-4
Total Debt to Enterprise0.36
Debt to Equity0.2

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Myriad Genetics, Inc.

2,600 employees
CEO: R. Bryan Riggsbee

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...